文献速递炎症性肠病

古塞奇尤单抗皮下诱导和维持治疗中重度活动性克罗恩病的疗效与安全性:3期GRAVITI研究结果

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study.
PubMed 文献 · Gastroenterology · 2025-03-18

GRAVITI 3期双盲安慰剂对照贯穿治疗研究纳入347例中重度活动性克罗恩病成人患者,随机接受古塞奇尤单抗400 mg皮下每4周诱导后100 mg每8周或200 mg每4周维持,或安慰剂。第12周临床缓解和內镜应答均显著优于安慰剂,第48周两个剂量组临床缓解和内镜应答仍显著优于安慰剂,安全性事件率未高于安慰剂。

要点

  • 第12周古塞奇尤单抗400 mg组临床缓解56.1% vs 安慰剂21.4%(Δ=34.9,P<.001)。
  • 第48周100 mg每8周组临床缓解60.0%、200 mg每4周组66.1% vs 安慰剂17.1%(P<.001)。
  • 不良事件率在古塞奇尤单抗组未高于安慰剂组。

核心结论

  • 皮下古塞奇尤单抗用于诱导和维持治疗对中重度活动性克罗恩病患者有效。
  • 安全性发现与古塞奇尤单抗在已批准适应症(包括溃疡性结肠炎)中的安全性一致。

研究设计与样本

  • 3期双盲、安慰剂对照、贯穿治疗研究,随机347例中重度活动性克罗恩病成人患者,按1:1:1分组。
  • 古塞奇尤单抗400 mg皮下每4周→100 mg皮下每8周组n=115;400 mg皮下每4周→200 mg皮下每4周组n=115;安慰剂组n=117。
  • 安慰剂组符合救援标准者自第16周起接受古塞奇尤单抗治疗;安全性评估至第48周。

主要发现

  • 第12周古塞奇尤单抗400 mg组临床缓解56.1% vs 安慰剂21.4%(Δ=34.9,P<.001)。
  • 第12周古塞奇尤单抗400 mg组内镜应答41.3% vs 安慰剂21.4%(Δ=19.9,P<.001)。
  • 第48周100 mg每8周组临床缓解60.0%(Δ=42.8)、200 mg每4周组66.1%(Δ=48.9)vs 安慰剂17.1%(各P<.001)。
  • 第48周100 mg每8周组内镜应答44.3%(Δ=37.5)、200 mg每4周组51.3%(Δ=44.6)vs 安慰剂6.8%(各P<.001)。
  • 在生物制剂初治患者和生物制剂应答不足或不耐受患者中均观察到疗效。

关键数值与推荐

  • 共同主要终点为第12周临床缓解和第12周内镜应答。
  • 其他多重控制终点包括第12周患者报告结局-2缓解、第12周临床应答、第24周临床缓解、第48周临床缓解和第48周内镜应答。
  • 所有多重控制终点均达到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Subcutaneous (SC) induction and maintenance with guselkumab was evaluated in adult participants with moderately to severely active Crohn's disease. METHODS: The Phase 3 double-blind, placebo-controlled, treat-through GRAVITI study randomized 347 participants 1:1:1 to guselkumab 400 mg SC every 4 weeks→100 mg SC every 8 weeks (n = 115), guselkumab 400 mg SC every 4 weeks→200 mg SC every 4 weeks (n = 115), or placebo (n = 117). Placebo participants meeting rescue criteria received guselkumab from week 16 onward. Co-primary endpoints were clinical remission at week 12 and endoscopic response at week 12. Additional multiplicity-controlled endpoints were Patient-Reported Outcome-2 remission (week 12), clinical response (week 12), clinical remission (week 24), clinical remission (week 48), and endoscopic response (week 48). Safety was assessed through week 48. RESULTS: All multiplicity-controlled endpoints were met. At week 12, significantly greater proportions of participants receiving guselkumab 400 mg achieved clinical remission vs placebo (56.1% vs 21.4%; Δ = 34.9; P < .001), and endoscopic response vs placebo (41.3% vs 21.4%; Δ = 19.9; P < .001). At week 48, significantly greater proportions of participants in both guselkumab groups (100 mg SC every 8 weeks: 60.0%, Δ = 42.8; 200 mg SC every 4 weeks: 66.1%, Δ = 48.9) achieved clinical remission vs placebo (17.1%; P < .001 each) and endoscopic response (44.3%, Δ = 37.5; 51.3%, Δ = 44.6; vs placebo 6.8%; P < .001 each). Efficacy was observed in both bionaive participants and those with inadequate response or intolerance to biologics. Adverse event rates were not greater in guselkumab groups vs placebo. CONCLUSION: Subcutaneous guselkumab for both induction and maintenance was efficacious in treating participants with moderately to severely active Crohn's disease. Safety findings were consistent with those of guselkumab in approved indications, including ulcerative colitis. (ClinicalTrials.gov, Number: NCT05197049.).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Hart A, Panaccione R, Steinwurz F, et al. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study. Gastroenterology. 2025. PMID: 40113101. doi:10.1053/j.gastro.2025.02.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。